Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | AURKA | O14965 | 7/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 5/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | LTK | P29376 | 1/20 | 1.00 |
| ▸ | TTK | P33981 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 1/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377224 | 1.00 | EGFR (1.00) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL6949133 | 0.91 | EGFR (0.82) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL15519470 | 0.90 | HDAC1 (1.00) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL13529060 | 0.89 | SRC (0.84) | EGFRKDRAURKAAURKBSRC | |
| Hydrochloric Acid SCHEMBL3535974 | 0.89 | EGFR (0.80) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL3578284 | 0.89 | KDR (0.98) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL13497826 | 0.88 | EGFR (0.80) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL12694312 | 0.88 | EGFR (0.79) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL6704281 | 0.88 | EGFR (0.80) | EGFRKDRAURKAAURKBSRC | |
| SCHEMBL31167326 | 0.86 | EGFR (0.78) | EGFRKDRAURKAAURKBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-06-11 | — | — | US | claimed |
| EP-3638268-A1 | COMPOSITIONS AND METHODS FOR TREATING A CLINICAL CONDITION THROUGH THE USE OF HEMATOPOIETIC STEM CELLS | Indiana University Research & Technology Corporation (US) | 2020-04-22 | — | — | EP | claimed |
| US-20200054681-A1 | COMPOSITIONS AND METHODS FOR TREATING A CLINICAL CONDITION THROUGH THE USE OF HEMATOPOIETIC STEM CELLS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-02-20 | — | — | US | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| WO-2018232272-A1 | COMPOSITIONS AND METHODS FOR TREATING A CLINICAL CONDITION THROUGH THE USE OF HEMATOPOIETIC STEM CELLS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-12-20 | — | — | WO | claimed |
| EP-2788504-B1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY OLOMOUC (CZ) | 2016-08-17 | — | — | EP | claimed |
| US-20140336073-A1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2014-11-13 | — | — | US | claimed |
| EP-2788504-A2 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | Palacky University, Olomouc (CZ) | 2014-10-15 | — | — | EP | claimed |
| WO-2013083098-A2 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2013-06-13 | — | — | WO | claimed |
| EP-2602330-A1 | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance | Palacky University, Olomouc (CZ) | 2013-06-12 | — | — | EP | claimed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-7563787-B2 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | MIIKANA THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20080200485-A1 | Kinase Inhibitors | MIIKANA THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20070142368-A1 | Substituted pyrazole compounds | MIIKANA THERAPEUTICS, INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | NR3C1, EZH2, MECP2 | EGFR 3808/4885KDR 3256/4885AURKA 1971/4885 |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | EGFR 358/4885KDR 328/4885AURKA 27/4885 |
| US-20080200485-A1 | Kinase Inhibitors | AURKC, AURKA, AURKB | EGFR 1016/4885KDR 2378/4885AURKA 2/4885 |
| US-20070142368-A1 | Substituted pyrazole compounds | AURKC, AURKA, AURKB | EGFR 1774/4885KDR 2577/4885AURKA 2/4885 |
| US-20090029992-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS | AURKC, AURKA, AURKB | EGFR 1774/4885KDR 2577/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.